Duobrii vs. Bryhali

• Are Duobrii and Bryhali the Same Thing?
• What Are Possible Side Effects of Duobrii?
• What Are Possible Side Effects of Bryhali?
• What Is Duobrii?
• What Is Bryhali?
• What Drugs Interact with Duobrii?
• What Drugs Interact with Bryhali?
• How Should Duobrii Be Taken?
• How Should Bryhali Be Taken?

Duobrii (halobetasol propionate and tazarotene) Lotion and Bryhali (halobetasol propionate) Lotion are indicated for the topical treatment of plaque psoriasis in adults.

Duobrii and Bryhali both contain a corticosteroid. Duobrii also contains a retinoid.

Side effects of Duobrii and Bryhali that are similar include rash.

Side effects of Duobrii that are different from Bryhali include contact dermatitis, application site pain, infected hair follicles, thinning skin, skin abrasions, stretch marks, and skin peeling.

Side effects of Bryhali that are different from Duobrii include upper respiratory tract infection, application site reactions, and high blood sugar (hyperglycemia).

Duobrii may interact with corticosteroids taken by mouth or injection and other products used on your skin that contain corticosteroids.

Bryhali may interact with other drugs.

Common side effects of Duobrii include:

• contact dermatitis,
• application site pain,
• infected hair follicles,
• thinning skin,
• skin abrasions,
• rash,
• stretch marks, and
• skin peeling

Common side effects of Bryhali include:

• upper respiratory tract infection,
• application site reactions (red, itchy rash), and high blood sugar (hyperglycemia).

Duobrii (halobetasol propionate and tazarotene) Lotion is a combination of a corticosteroid and a retinoid indicated for the topical treatment of plaque psoriasis in adults.

Bryhali (halobetasol propionate) Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in adults.

Duobrii Lotion may interact with corticosteroids taken by mouth or injection, or other products used on your skin that contain corticosteroids. Tell your doctor all medications and supplements you use. Duobrii Lotion is not recommended for use during pregnancy; it may harm a fetus. A negative result for pregnancy should be obtained within 2 weeks prior to Duobrii Lotion therapy, which should begin during menstruation. Females of reproductive potential are advised to use effective contraception during treatment with Duobrii Lotion. It is unknown if Duobrii passes into breast milk.

Bryhali may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Bryhali; it is unknown how it would affect a fetus. It is unknown if Bryhali passes into breast milk. Systemically administered corticosteroids pass into breast milk and could cause adverse effects. It is unknown if topical administration of corticosteroids such as Bryhali could cause unwanted effects in nursing infants. Consult your doctor before breastfeeding.

Apply a thin layer dose of Duobrii Lotion to the affected areas once daily.

Treatment beyond 8 weeks is not recommended.